CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic...
Virtual KOL Event is scheduled for Today, April 27th @ 10:30 AM ETAUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) --...
Strengthens therapeutic development programs with key hires in Pharmacology and ToxicologyVANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- Bright...
Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ETCAMBRIDGE, Mass., April 27,...
FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with...
Study concludes the utilization of T2 Magnetic Resonance (T2MR®) provides faster time to detection, faster time to targeted therapy, and...
Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its...
Additional case studies support the broad potential of AC5® Advanced Wound System in chronic and non-healing woundsFRAMINGHAM, Mass., April 27,...
CLEVELAND, April 27, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization...
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on...
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, April 27, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), the...
All common shares will continue to be listed and tradable on the NasdaqVANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE)...
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment- - -Topline results for Phase 3 Pivotal Cardigan I and Cardigan...
OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed...
Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of...
Enhanced Infusion System (EIS) Patented IV add-in infusion system reduces the risk of infection and embolism, saves time and money....
SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the...
– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – –...